4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Context Therapeutics Inc. (CNTX) operates in the Biotechnology industry and is headquartered in Philadelphia, United States with about 15 employees. Its market capitalization is roughly $57 million. In the fiscal year ended 2025-12-31, CNTX reported $0M in revenue and ($36M) in net income.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($40M) | ($30M) | ($25M) | ($15M) | — |
| Net Income | ($36M) | ($27M) | ($24M) | ($15M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($9M) | ($14M) | ($11M) | ($10M) | ($6M) |
| Net Income | ($9M) | ($13M) | ($10M) | ($9M) | ($5M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $68M | $98M | $16M | $38M | — |
| Total Liabilities | $8M | $3M | $4M | $3M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CNTX viewer.
About TickerBase · Data methodology & sources